What is the recommended dosing and renal adjustment for nirmatrelvir/ritonavir (Paxlovid) in a non‑hospitalized COVID‑19 patient within five days of symptom onset, and what are the contraindications?

Paxlovid Dosing and Renal Adjustment

For non-hospitalized COVID-19 patients within 5 days of symptom onset, administer nirmatrelvir 300 mg (two 150 mg tablets) with ritonavir 100 mg twice daily for 5 days; reduce to nirmatrelvir 150 mg with ritonavir 100 mg twice daily for moderate renal impairment (eGFR 30-59 mL/min), and avoid use in severe renal impairment (eGFR <30 mL/min). 1

Standard Dosing

The FDA-approved regimen consists of:

• Nirmatrelvir 300 mg (two 150 mg tablets) + ritonavir 100 mg (one tablet)
• All three tablets taken together twice daily for 5 days
• Can be administered with or without food
• Must initiate treatment as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset 1

Recent evidence suggests immediate initiation (Day 0) provides superior outcomes compared to delayed initiation, with significantly lower post-acute mortality (HR 0.51) versus Day 1 initiation (HR 0.66), and no significant benefit when started on Day 2 or later 2. This reinforces the critical importance of prescribing immediately upon diagnosis rather than waiting.

Renal Dose Adjustments

Moderate Renal Impairment (eGFR 30-59 mL/min):

• Nirmatrelvir 150 mg (one 150 mg tablet) + ritonavir 100 mg
• Both tablets taken together twice daily for 5 days 1

Severe Renal Impairment (eGFR <30 mL/min):

• Not recommended per FDA labeling 1
• However, emerging data from the EPIC-SRI trial demonstrates that a modified regimen (300/100 mg loading dose on Day 1, followed by 150/100 mg once daily on Days 2-5) is well-tolerated in patients with severe renal impairment, including those on intermittent hemodialysis, achieving adequate drug exposure without treatment-related adverse events 3. This represents a potential future option but is not currently FDA-approved.

Normal Renal Function or Mild Impairment (eGFR ≥60 mL/min):

• Standard dosing applies

Hepatic Adjustments

• No adjustment needed for mild to moderate hepatic impairment
• Not recommended in severe hepatic impairment (Child-Pugh Class C) 1

Contraindications

Absolute Contraindications:

1. Clinically significant hypersensitivity to nirmatrelvir or ritonavir 1
2. Co-administration with drugs highly dependent on CYP3A for clearance where elevated concentrations cause serious/life-threatening reactions 1
3. Co-administration with potent CYP3A inducers that may reduce nirmatrelvir/ritonavir concentrations, leading to loss of virologic response 1

Critical Drug Interaction Considerations:

Before prescribing, you must:

• Review all patient medications for CYP3A interactions
• Ritonavir is a strong CYP3A inhibitor and also inhibits CYP2D6, P-gp, and OATP1B1 1
• High-risk medications requiring particular attention include immunosuppressants (tacrolimus, cyclosporine) and calcium channel blockers 1
• Determine if concomitant medications require dose adjustment, temporary interruption, or additional monitoring 1

The FDA includes a boxed warning specifically about these drug interactions, emphasizing that ritonavir may lead to potentially severe, life-threatening, or fatal events from elevated concentrations of concomitant medications 1.

Clinical Context

The American College of Physicians supports use of nirmatrelvir-ritonavir for symptomatic patients with confirmed mild to moderate COVID-19 who are within 5 days of symptom onset and at high risk for progression to severe disease 4. Real-world data confirms low hospitalization rates (4.9%) with similar efficacy to molnupiravir, though dysgeusia occurs significantly more frequently with Paxlovid 5.

Common Pitfalls to Avoid

• Delaying initiation: Start immediately upon diagnosis, not on Day 4 or 5 of symptoms
• Missing drug interactions: The most common serious error—always screen for CYP3A substrates, particularly immunosuppressants
• Incorrect renal dosing: Calculate eGFR before prescribing; underdosing in normal renal function or overdosing in moderate impairment both compromise outcomes
• HIV resistance risk: In patients with uncontrolled or undiagnosed HIV-1 infection, ritonavir exposure may lead to protease inhibitor resistance 1
• Hypersensitivity reactions: Anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported—discontinue immediately if these occur 1